Healthcare mergers and acquisitions surged to $65 billion in the first quarter of 2026, the highest since 2020, fueled by looming patent expirations on blockbuster drugs like Merck’s Keytruda. Pharma companies are acquiring innovative biotech firms to fill revenue gaps with next-generation therapies. Deals include Gilead’s $8.2 billion buy of Arcelix and Lilly’s $7.8 billion purchase of Cantesa Pharmaceuticals. Additionally, Indian biotech firm Anthem Biosciences, founded by Ajay Bhardwaj, has grown significantly by providing cost-effective outsourcing services to pharma companies, recently going public with a $4.5 billion market cap. The trend is expected to continue as IPO opportunities remain limited for many biotechs.
Gilead Sciences reported its strongest revenue growth in a decade, with Q3 revenues rising 16% excluding Veklury, driven mainly by a strong HIV franchise. However, the company faces challenges ahead as its key HIV drug Biktarvy will be subject to Med...
Gilead Sciences reported strong Q3 results with growth in HIV treatments and oncology drugs like Trodelvy. However, Medicare pricing changes will cut Biktarvy revenue by $1.5 billion annually starting in 2028, increasing Gilead's dependence on HIV pr...
Gilead Sciences reported strong Q3 results with revenue of $8.3 billion, beating analyst expectations and showing growth both quarterly and yearly. Sales of Trodelvy, a breast cancer drug, rose 41.7% year-over-year to $506 million. The company also a...
Assembly Biosciences has dosed the first two participants in a Phase 2 study of ABI-6250, an oral small-molecule drug for chronic hepatitis delta virus (HDV) infection. The study will enroll about 80 participants to evaluate safety, pharmacokinetics,...
Eli Lilly, Merck, and Gilead Sciences are set to report their Q3 2026 earnings on October 29, with Eli Lilly facing lowered EPS estimates amid strong GLP-1 drug demand, Merck dealing with tough comparisons for its cancer drug Keytruda, and Gilead man...
